CATX.US Perspective Therapeutics Inc.

Healthcare Health Care Equipment & Supplies USA Stocks
0.9431 USD
Close of Nov 13, 2026
0.7795 6.16
Market cap
USD 114M
P/E
-
P/B
0.35x
ROE
-38.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CATX.US undervalued?

Graham number

The Graham number of Perspective Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Perspective Therapeutics Inc. fundamental analysis

No fundamental analysis for Perspective Therapeutics Inc. yet.

Perspective Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Perspective Therapeutics Inc.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, s…

Full company profile